SG/CALL/BRISTOL-MYERS SQUIBB/50/0.1/17.01.25 | Delayed Deutsche Boerse AG 12:57:44 2024-06-26 EDT | ||
| 0.11 EUR | +10.00% |
|
| Current month | +28.21% | ||
| 1 month | +20.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 0.11 | +10.00% |
| 24-06-25 | 0.1 | 0.00% |
| 24-06-24 | 0.1 | 0.00% |
| 24-06-21 | 0.1 | +13.64% |
| 24-06-20 | 0.088 | +14.29% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 12:57 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3VV9 |
| ISIN | DE000SW3VV97 |
| Date issued | 2023-09-22 |
| Strike | 50 $ |
| Maturity | 2025-01-17 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 1.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.21 € |
|---|---|
| Lowest since issue | 0.066 € |
| Spread | 0.01 € |
| Spread % | 8.33% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.19
USD
Average target price
53.19
USD
Spread / Average Target
+26.08%
- Stock Market
- Warrants
- Warrant
